Critical Limb Ischemia - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Critical Limb Ischemia - Pipeline Review, H2 2018’, provides an overview of the Critical Limb Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia

- The report reviews pipeline therapeutics for Critical Limb Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Critical Limb Ischemia therapeutics and enlists all their major and minor projects

- The report assesses Critical Limb Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Critical Limb Ischemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AnGes Inc

apceth Biopharma GmbH

Athersys Inc

BiogenCell Ltd

Caladrius Biosciences Inc

Cynata Therapeutics Ltd

Hemostemix Inc

Histocell SL

ID Pharma Co Ltd

Integene International ...

AnGes Inc

apceth Biopharma GmbH

Athersys Inc

BiogenCell Ltd

Caladrius Biosciences Inc

Cynata Therapeutics Ltd

Hemostemix Inc

Histocell SL

ID Pharma Co Ltd

Integene International Holdings LLC

Juventas Therapeutics Inc

Kang Stem Biotech Co Ltd

Kasiak Research Pvt Ltd

Neurofx Inc

Nissan Chemical Industries Ltd

Pharmicell Co Ltd

Pluristem Therapeutics Inc

ReNeuron Group Plc

Reven Pharmaceuticals Inc

Rexgenero Ltd

Symic Biomedical Inc

TaiGen Biotechnology Co Ltd

U.S. Stem Cell Inc

VESSL Therapeutics Ltd

ViroMed Co Ltd

YiChang Humanwell Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Critical Limb Ischemia – Overview 6

Critical Limb Ischemia – Therapeutics Development 7

Critical Limb Ischemia – Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 5

Critical Limb Ischemia – Overview 6

Critical Limb Ischemia – Therapeutics Development 7

Critical Limb Ischemia – Therapeutics Assessment 16

Critical Limb Ischemia – Companies Involved in Therapeutics Development 24

Critical Limb Ischemia – Drug Profiles 35

Critical Limb Ischemia – Dormant Projects 124

Critical Limb Ischemia – Discontinued Products 126

Critical Limb Ischemia – Product Development Milestones 127

Appendix 137

List of Tables

List of Tables

Number of Products under Development for Critical Limb Ischemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Critical Limb Ischemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Critical Limb Ischemia – Pipeline by AnGes Inc, H2 2018

Critical Limb Ischemia – Pipeline by apceth Biopharma GmbH, H2 2018

Critical Limb Ischemia – Pipeline by Athersys Inc, H2 2018

Critical Limb Ischemia – Pipeline by BiogenCell Ltd, H2 2018

Critical Limb Ischemia – Pipeline by Caladrius Biosciences Inc, H2 2018

Critical Limb Ischemia – Pipeline by Cynata Therapeutics Ltd, H2 2018

Critical Limb Ischemia – Pipeline by Hemostemix Inc, H2 2018

Critical Limb Ischemia – Pipeline by Histocell SL, H2 2018

Critical Limb Ischemia – Pipeline by ID Pharma Co Ltd, H2 2018

Critical Limb Ischemia – Pipeline by Integene International Holdings LLC, H2 2018

Critical Limb Ischemia – Pipeline by Juventas Therapeutics Inc, H2 2018

Critical Limb Ischemia – Pipeline by Kang Stem Biotech Co Ltd, H2 2018

Critical Limb Ischemia – Pipeline by Kasiak Research Pvt Ltd, H2 2018

Critical Limb Ischemia – Pipeline by Neurofx Inc, H2 2018

Critical Limb Ischemia – Pipeline by Nissan Chemical Industries Ltd, H2 2018

Critical Limb Ischemia – Pipeline by Pharmicell Co Ltd, H2 2018

Critical Limb Ischemia – Pipeline by Pluristem Therapeutics Inc, H2 2018

Critical Limb Ischemia – Pipeline by ReNeuron Group Plc, H2 2018

Critical Limb Ischemia – Pipeline by Reven Pharmaceuticals Inc, H2 2018

Critical Limb Ischemia – Pipeline by Rexgenero Ltd, H2 2018

Critical Limb Ischemia – Pipeline by Symic Biomedical Inc, H2 2018

Critical Limb Ischemia – Pipeline by TaiGen Biotechnology Co Ltd, H2 2018

Critical Limb Ischemia – Pipeline by U.S. Stem Cell Inc, H2 2018

Critical Limb Ischemia – Pipeline by VESSL Therapeutics Ltd, H2 2018

Critical Limb Ischemia – Pipeline by ViroMed Co Ltd, H2 2018

Critical Limb Ischemia – Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H2 2018

Critical Limb Ischemia – Dormant Projects, H2 2018

Critical Limb Ischemia – Dormant Projects, H2 2018 (Contd..1), H2 2018

Critical Limb Ischemia – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Critical Limb Ischemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Critical Limb Ischemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports